Literature DB >> 1691998

Possible involvement of endothelium in the responses of various vasoactive agents in rabbit isolated perfused kidney.

Z S Ercan1, A S Soydan, R K Türker.   

Abstract

1. Perfusion of the kidney with methylene blue, a soluble guanylate cyclase inhibitor, significantly enhanced the vasoconstrictor effects of angiotensin II, noradrenaline and phenylephrine but significantly reduced the vasodilator effect of acetylcholine without altering that of iloprost. 2. In the kidneys, which were perfused with Triton X-100 to remove endothelium, acetylcholine-induced vasodilation was completely abolished and angiotensin II-, noradrenaline- and phenylephrine-induced vasoconstriction was greatly reduced. 3. The vasodilator effect of iloprost was unchanged after perfusion of kidney with Triton X-100. 4. Neither methylene blue nor Triton X-100 significantly altered urine volume form normal and angiotensin II induced increase of urine volume. 5. These results were taken as evidence for the involvement of renal vascular endothelium originated EDRF in the responses of various vasoactive agents in the rabbit isolated perfused kidney.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1691998     DOI: 10.1016/0306-3623(90)90902-x

Source DB:  PubMed          Journal:  Gen Pharmacol        ISSN: 0306-3623


  3 in total

1.  Cytokine-induced expression of a nitric oxide synthase in rat renal tubule cells.

Authors:  B A Markewitz; J R Michael; D E Kohan
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

2.  In vitro Release of Eosinophil Proteins in Allergic and Atopic Dermatitis Patients.

Authors:  L K Poulsen; C M Reimert; C Bindslev-Jensen
Journal:  Mediators Inflamm       Date:  1994       Impact factor: 4.711

3.  Possible involvement of endothelin peptides and L-arginine-nitric oxide pathway on the effect of endotoxin in the rabbit isolated perfused kidney.

Authors:  K Ozsan; R K Türker; Z S Ercan
Journal:  Mediators Inflamm       Date:  1994       Impact factor: 4.711

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.